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Abstract Protein homeostasis is fundamental for cell
function and survival, because proteins are involved in all
aspects of cellular function, ranging from cell metabolism
and cell division to the cell’s response to environmental
challenges. Protein homeostasis is tightly regulated by the
synthesis, folding, trafficking and clearance of proteins, all
of which act in an orchestrated manner to ensure proteome
stability. The protein quality control system is enhanced by
stress response pathways, which take action whenever the
proteome is challenged by environmental or physiological
stress. Aging, however, damages the proteome, and such
proteome damage is thought to be associated with aging-
related diseases. In this review, we discuss the different
cellular processes that define the protein quality control
system and focus on their role in protein conformational
diseases. We highlight the power of using small organisms
to model neurodegenerative diseases and how these models
can be exploited to discover genetic modulators of protein
aggregation and toxicity. We also link findings from small
model organisms to the situation in higher organisms and
describe how some of the genetic modifiers discovered in
organisms such as worms are functionally conserved
throughout evolution. Finally, we demonstrate that the non-
coding genome also plays a role in maintaining protein
homeostasis. In all, this review highlights the importance
of protein and RNA homeostasis in neurodegenerative
diseases.
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Maintaining a healthy proteome is important to ensure cell
survival and function. The cell maintains a healthy pro-
teome through a series of complex and tightly regulated
surveillance systems (Fig. 1). These systems ensure that
each protein is properly folded or assembled in a state that
is required for it to perform its function in the cell.
After the synthesis of a nascent polypeptide chain, the
protein’s amino acid sequence determines whether or not
the protein becomes folded, and whether or not chaperone
proteins are required for its folding (Fig. 1a, b). Some
proteins are thought to exist in a predominantly ‘‘un-
folded’’, ‘‘disordered’’ or ‘‘intrinsically unstructured’’ state
([1], also reviewed in [2, 3]). Such proteins are typically
involved in transcription, in signaling pathways and in
protein networks ([4], also reviewed in [5, 6]). In mam-
mals, about half of all possible proteins are predicted to
have long disorganized regions and about 25 % are esti-
mated as being intrinsically unstructured [2]. Other
proteins have domains within their amino acid sequence
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that can fold spontaneously, whereas other large, multi-
subunit proteins require molecular chaperones to assist in
folding to their native state, as shown in in vitro studies [7–
11].
The molecular chaperones that cooperate in the de novo
folding or refolding process are subdivided into different
classes, which include the Hsp70 system, the small chap-
erones, the chaperonins and the Hsp90 system [11–14]. In
the case of de novo synthesis, chaperones protect the nas-
cent polypeptide chain from aberrant contacts with other
domains of the same proteins and from aggregation with
other proteins (Fig. 1b) ([13, 14], also reviewed in [12,
15]). As a protein is synthesized, it is transiently unfolded
and its hydrophobic regions are exposed. Hsp70 is able to
recognize these regions and it binds to the protein substrate
via its peptide-binding site in an ATP-dependent manner
(reviewed in [12, 15, 16]). Hsp70 holds the substrate in an
extended conformation, stabilizing it and preventing pre-
mature misfolding and aggregation. Next, the substrate can
be transferred to another chaperone system, such as the
chaperonins, where folding takes place and a three-di-
mensional structure is acquired (reviewed in [12, 16, 17]).
When misfolded proteins accumulate, unfolded protein
responses can increase the levels of chaperones, which are
then able to restore the proteins to their properly folded
form (Fig. 1c, d, reviewed in [16, 18–21]). Such an accu-
mulation of misfolded protein is just one of the types of
stress that can trigger unfolded protein responses. Unfolded
protein responses are mechanisms that are highly con-
served from yeast to humans and that are induced upon
environmental and physiological stress, such as thermal or
oxidative stress (reviewed in [22–24]). In one of these
pathways thought to respond to the accumulation mis-
folded proteins in the cytosol, heat shock factor 1 (HSF-1)
acts as a master transcriptional regulator. HSF-1 is acti-
vated upon phosphorylation, after which it translocates
from the cytosol to the nucleus to bind to the so-called heat












































Fig. 1 Quality control of cellular proteins. When a protein is
synthesized, it can acquire its native state in a chaperone-independent
(a) or dependent (b) manner. Upon environmental stress or mutations,
the protein may either not acquire its native state or lose it, both
leading to misfolding (c). Here, the misfolded protein can be refolded
back to its functional conformation with the aid of chaperones (d); or
sent to degradation via the ERAD (e), the ubiquitin–proteasome
system (f) or autophagy (g). Alternatively, it can be redirected to the
JUNQ for posterior refolding or degradation by the proteasome (h) or
it can be permanently sequestered in the IPOD (i) or aggresome (j)
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heat shock genes. These genes are then translated into
proteins that assist in the refolding of misfolded proteins
into functionally active proteins, in preventing unspecific
interactions, or in mediating their degradation (Fig. 1d)
(reviewed in [19, 22]).
Another strategy used by the cell to restore protein
homeostasis is the unfolded protein response that is asso-
ciated with the endoplasmic reticulum (ER) (Fig. 1e, also
reviewed in [18, 25, 26]). The ER is the organelle where
proteins enter the secretory pathway to acquire post-
translational modifications, after which they are delivered
to their corresponding organelle, fixed in the plasma
membrane or shuttled outside of the cell to perform their
function [27]. If misfolded proteins accumulate, the ER-
associated degradation (ERAD) pathway is activated
through signal transduction pathways that are mediated by
three upstream effectors: inositol-requiring protein 1
(IRE1), activating transcription factor (ATF)-6 and PKR-
like endoplasmic reticulum kinase (PERK).
IRE1, ATF-6 and PERK mediate three distinct path-
ways. Firstly, IRE1 is a transmembrane protein kinase that
activates itself by auto-phosphorylation and mediates
splicing of Hac1 in yeast and XBP-1 in eukaryotes [28–32].
IRE1 is known to promote the transcription of three groups
of genes: stress-responsive genes including molecular
chaperones and folding enzymes, genes involved in ERAD
and genes involved in ER trafficking [33–35]. Secondly,
ATF-6 is a transmembrane protein with a transcription
factor domain (leucine zipper) that translocates from the
ER lumen to the Golgi apparatus to be cleaved by proteases
[36, 37]. This proteolysis releases the ATF-6 cytosolic
fragment, which then enters the nucleus to induce the
transcription of ER-resident chaperones and the transcrip-
tion factor XBP-1, thereby increasing ER protein quality
control capacity [29, 37–39]. Thirdly, PERK is a trans-
membrane kinase protein that phosphorylates the alpha-
subunit of the eukaryotic translation initiation factor 2a
(eIF2a), thus preventing the binding of the initiator
tRNA(Met) to the ribosomal complex, necessary for
translation initiation [40–42]. This results in an overall
reduction in protein synthesis, thereby attenuating the
accumulation of misfolded proteins at the ER.
Protein degradation
If an aberrant protein cannot be folded back into its native
state by the molecular chaperones, then it can be eliminated
by two proteolytic systems, the proteasome and autophagy
(Fig. 1f, g). In the degradation via the ERAD pathway, the
ER cooperates tightly with the ubiquitin–proteasome sys-
tem (UPS) to recognize, mark and traffic the misfolded
proteins to the cytosol for degradation (Fig. 1e, reviewed in
[18, 43–45]). The exact mechanisms that allow the cell to
discriminate misfolded proteins from correctly folded
proteins are not fully understood (reviewed in [44, 46, 47]).
However, the current notion is that misfolded proteins can
be recognized by molecular chaperones (the HSP70 family
of proteins) and co-chaperones (the DnaJ/HSP40 family of
proteins) [48–51].
An example that illustrates this recognition is the
immunoglobulin binding protein (BiP), an HSP70 chaper-
one that recognizes and binds to the hydrophobic regions of
misfolded proteins, thereby preventing their aggregation
[49–53]. The binding of the ERAD substrate to BiP and its
subsequent release depends on the conversion of ADP to
ATP, a process regulated by ERdj proteins, which are part
of the DnaJ/Hsp40 family of co-chaperones, and the
nucleotide exchange factors GRP170 and BAP/Sil1 [48,
52]. These factors stimulate the ATPase activity of BiP and
stabilize its binding to the misfolded protein [54–58]. The
ERdj co-chaperones have also been shown to bind directly
to unfolded proteins, thus maintaining them in a soluble
state to be later recruited by BiP [48, 59]. After the mis-
folded protein has been identified, it is poly-ubiquitinated
to be subsequently targeted for degradation [60–62].
Ubiquitination is a sequential three-step process that
marks proteins destined for the proteasome (Fig. 1f). It
starts with the activation of ubiquitin (a small 76 amino
acid protein) by the activating enzyme E1, followed by
binding of ubiquitin to the active site of the ubiquitin-
carrier protein E2 and, finally, transfer of the ubiquitin
molecule to the substrate in a reaction catalyzed by the
ubiquitin protein ligase E3. At least four ubiquitin mole-
cules must be bound to the ERAD substrate for it to be later
recognized by the proteasomal machinery [63, 64]. Fol-
lowing this step, the misfolded proteins are delivered to the
proteasome (a process called retrotranslocation) and the
ubiquitin molecules are removed from the substrate prior to
degradation by the deubiquitinating enzymes and recycled
[65–67]. The proteasome is a barrel-shaped, multicatalytic
proteinase where proteolysis occurs and proteins are
cleaved into peptides 2–30 amino acid long [68].
The second proteolytic system, autophagy (‘‘self-eat-
ing’’), is a cellular degradation mechanism that eliminates
cytosolic components, organelles and pathogens via lyso-
somes (Fig. 1g, [69–72]). It is the part of the cell that
ensures protein and organelle turnover, where old cellular
components are degraded and recycled molecules become
available for cell metabolism [70, 71, 73]. For the purpose
of this review, we discuss only the role of autophagy as a
protein quality control system.
Autophagy can be classified into three categories:
macroautophagy, microautophagy and chaperone-mediated
autophagy (CMA). In macroautophagy, a newly formed
double membrane vesicle engulfs the cytosolic material,
forming the autophagosome. The autophagosome then
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fuses with an endosome or lysosome, giving rise to the
autolysosome where degradation takes place through the
action of hydrolytic enzymes (Fig. 1g) [71]. The double
membrane that surrounds the autophagosome is derived
from the ER, the mitochondria or the plasma membrane
[74–78]. In yeast, autophagy is a multi-step process that
requires at least 37 autophagy-related (ATG) genes [79–
89]. The majority of the ATG genes have shown to be
functionally conserved in mammals [90, 91]. In microau-
tophagy, small molecules from the cytoplasm are
internalized by the lysosome through invagination of its
own membrane [70, 73]. In contrast to autophagy and
CMA, much less is known about microautophagy [92].
CMA differs from the former two forms of autophagy in
that it does not involve membrane reorganization. Instead,
substrates with a KFERQ amino acid motif are recognized
by an HSP70 cytosolic chaperone, Hsc70, that binds and
delivers them to the CMA receptor at the lysosome [93–
96]. Here, the substrate is unfolded before it is translocated
into the lumen of the lysosome for degradation, which is
assisted by Hsc73, an intralysosomal HSP70 chaperone
[97, 98].
Crosstalk exists between the UPS and autophagy.
Chronic low-level proteasomal inhibition is known to be
sufficient to activate autophagy, and it has been suggested
that ubiquitinated proteins may also be eliminated through
this pathway [99–101]. It has also been proposed that
macroautophagy may occur as a compensatory mechanism
when either the UPS or CMA is impaired [102, 103].
Protein compartmentalization
An alternative pathway for misfolded proteins is the
sequestration into specialized protein quality control
compartments where they can be either recovered or per-
manently sequestered (Fig. 1h, i, j) ([104–109], also
reviewed in [110, 111]). Distinct quality control compart-
ments harbor different species of misfolded proteins and
are evolutionary conserved from yeast to mammals [105,
107–109, 112, 113]. Ubiquitinated misfolded cytosolic
proteins are assigned to the juxtanuclear quality control
compartment (JUNQ, Fig. 1h). These soluble, mobile
misfolded proteins can subsequently be recovered by the
molecular chaperone Hsp104 and either refolded back into
functionally active proteins or degraded by the protea-
somes localized nearby (Fig. 1h) [108, 112]. Non-
ubiquitinated misfolded proteins—comprising amyloido-
genic proteins—are redistributed to the insoluble protein
deposit (IPOD, Fig. 1i). This compartment is localized at
the cell periphery and is known to contain insoluble and
immobile species, which are not recoverable and seem to
remain terminally sequestered there (Fig. 1i) [108]. More
recently, it has been proposed that there are no pre-existing
compartments in the cell, and that soluble ubiquitinated
misfolded proteins (but not the non-ubiquitinated amy-
loidogenic type) may coalesce and form transient structures
termed ‘Q bodies’ that eventually mature into the JUNQ
compartments [104].
Much research has focused on finding out whether the
redistribution of misfolded proteins to these spatial
cytosolic compartments is a random event or whether it
depends on the concerted action of sorting factors. Evi-
dence suggests that the latter is the case, and that sorting
factors interact with chaperones to deliver misfolded pro-
teins to each compartment [105]. For example, upon
physiological stress, Btn2 (a Hook family protein involved
in linking organelles to microtubules) was shown to asso-
ciate either with the yeast small heat shock protein Hsp42
to assign misfolded proteins to the IPOD or with the
chaperone Sis1 to guide misfolded proteins to the JUNQ
[105, 107].
Another type of cytosolic compartment—the aggre-
some—is localized at the microtubule organizing center
(MTOC) and is formed when the proteasome is unable to
clear misfolded proteins properly (Fig. 1j) [114]. Aggre-
some formation is accompanied by redistribution of
vimentin, an intermediary filament that acquires a cage-like
structure in the aggresome. Ubiquitinated misfolded pro-
teins depend on microtubules to be transported to the
aggresome, this being done by the dynein/dynactin com-
plex (Fig. 1j) [115]. Interestingly, the JUNQ shares several
properties with the aggresome, including its perinuclear
localization, and the presence of chaperones and ubiquiti-
nated misfolded proteins [108, 114]. It has also recently
been shown to functionally associate with the MTOC and
vimentin [112]. Indeed, continuous accumulation of mis-
folded proteins in the JUNQ is thought to turn it in an
aggresome over time [112].
Similar structures to aggresomes are the so-called
aggresome-like induced structures (ALIS), which were
originally discovered in dendritic cells but were later also
found in other type of cells [109, 116]. The ALIS is a
transient structure with peripheral and juxtanuclear local-
ization. It is induced under a wide variety of stress
conditions (e.g., heat shock, starvation, oxidative stress,
inflammation) and clusters newly synthesized, ubiquiti-
nated misfolded proteins [106, 109]. ALIS substrates can
also be cleared by the proteasome and lysosome [106].
Cell division could be considered as yet another protein
quality control system that sequesters misfolded, aggre-
gated proteins (reviewed in [117, 118]). Studies in bacteria
and yeast have shown that accumulation of protein aggre-
gates reduces the fitness of these cells, a problem partially
resolved by asymmetric division: these protein deposits are
retained in the aging mother cell while the daughter cells
are freed from damaged proteins, a process also known as
4030 O. Sin, E. A. A. Nollen
123
replicative rejuvenation [119–123]. In budding yeast, it has
been shown that misfolded proteins sorted either to the
JUNQ or IPOD remain in the mother cell after asymmetric
cell division, thus avoiding passage of these species onto
the daughter cells [124]. Follow-up work from the same
group extended this observation to mammalian cells, where
the JUNQ (but not the IPOD) continues to be inherited
asymmetrically, thereby always freeing one of the two
daughter cells from proteotoxicity [112].
While much is now known about the sophisticated
quality control mechanisms that the cell has evolved to
ensure proper protein homeostasis, several questions
remain to be answered. We know that the cell relies on the
concerted action of chaperones to prevent an unfolded or
misfolded protein interacting aberrantly with other proteins
until it can be refolded back into its native state. In case
this is not possible, the aberrant protein is sent to be
degraded via the ubiquitin–proteasome system or by
autophagy. However, it is still not known how the cell
chooses one mechanism of degradation over the other or
whether the two mechanisms occur simultaneously.
Another unknown relates to protein compartmentaliza-
tion—yet another strategy for putting away proteins that
need to be degraded or permanently sequestered. It has not
yet been established how the cell can differentiate between
degradable and non-degradable proteins and shuttle them
to different subcellular compartments. Finally, another
important question is how protein quality control changes
during aging. Aging itself may be the contributing factor
for progressive deterioration of protein homeostasis,
impairing the ability of the protein quality control system
to handle the equilibrium between protein folding and
degradation.
Protein misfolding and aggregation
in neurodegenerative diseases
The effects of progressive deterioration of protein home-
ostasis are thought to play a role in age-related
neurodegenerative diseases. The presence of protein
aggregates in the brain is namely a hallmark shared by
several neurodegenerative diseases, including Parkinson’s
(PD), Alzheimer’s (AD) and Huntington’s disease (HD)
(reviewed in [125, 126]). In these diseases, it is not yet
clear why proteins accumulate into aggregates and how this
relates to pathogenesis.
Protein aggregation and its relationship to aging and
neurodegeneration have also been widely studied in animal
models. Evidence from several animal models suggests
that, as the animal ages, the cell’s stress response systems
become less efficient and less capable of maintaining a
balanced proteome [127–133]. This could lead to the
progressive accumulation of cytotoxic aggregation-prone
disease proteins that cannot be cleared, ultimately resulting
in toxicity and cell death [100, 134–137]. In the round-
worm Caenorhabditis elegans, a model organism much
used to study aging, protein aggregation has been shown to
occur during aging and to affect the lifespan of the
organism [138–140]. As previously discussed, when a
protein misfolds it exposes its aggregation-prone domains
to the cellular environment—domains that would otherwise
be structurally concealed—thereby facilitating the likeli-
hood of aberrant interactions with other proteins,
potentially leading to proteotoxicity. Such proteotoxicity is
proposed to play a role in protein conformational diseases
in humans, including PD, AD and HD.
The type of aggregates that are formed varies for different
neurodegenerative diseases. Frontotemporal lobar degener-
ation with fused in sarcoma is an example of a
neurodegenerative disease that is characterized by the
presence of amorphous, non-amyloidogenic aggregates
([141, 142], also reviewed in [143]). On the other hand, the
common neuropathological feature of PD, AD and HD is the
presence of an aggregation-prone disease protein that
acquires amyloidogenic properties, causing it to form
intracellular amyloid aggregates or extracellular amyloid
plaques in the brains of patients (reviewed in [125, 126,
144]). The amyloids present in these neurodegenerative
diseases can be distinguished from other amorphous,
unstructured aggregates because they are organized, insol-
uble fibrils with a cross-beta structure and because they can
be detected by specific amyloid-binding dyes, namely
Congo red and thioflavin T (reviewed in [145, 146]). It is
interesting to note that—despite their differences in amino
acid sequence and function—several unrelated aggregation-
prone disease proteins have one thing in common: in disease
they are present as amyloid. This suggests that their ability to
form amyloid is related to disease and that they may cause
proteotoxicity in a similar manner.
In vitro studies have made clear that virtually any pro-
tein can form amyloid fibrils under certain conditions. Such
conditions include low pH, high temperature and high
pressure [147–154]. Native proteins are known to exist in
equilibrium with their partially unfolded state, and when
they are destabilized by certain conditions or mutations, the
equilibrium shifts towards amyloid formation. Predicting
aggregation-prone regions in proteins is now possible using
bioinformatic tools. Examples of such tools are TANGO,
which can specifically identify regions prone to form beta
sheets, and Waltz, which can distinguish between amyloid
sequences and amorphous beta-sheet aggregates [155,
156].
A proposed mechanism for amyloid formation is
depicted in Fig. 2. Most of our understanding of this
pathway has come not only from in vitro studies of
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aggregation-prone proteins, including amyloid-beta (seen
in AD) and alpha-synuclein (seen in PD) but also from
studies of globular proteins, including human lysozyme,
superoxide dismutase 1, transthyretin and the acylphos-
phatase from the archaea Sulfolobus solfataricus (reviewed
in [17, 125, 126, 146, 147]). One common step of amyloid
formation appears to be the conversion of the monomeric,
native state protein into an oligomeric intermediate state
(Fig. 2). An oligomer is a small and transient cluster of
protein molecules that has no fibrillar structure and is of
low molecular weight [157–159]. These oligomers can then
form protofibrils, which are fibrils 6 to 8 nm in diameter,
about 200 nm in length and known to contain beta sheets
detectable by Congo red and thioflavin T staining (Fig. 2)
[160, 161]. Protofibrils can then convert into amyloid fibrils
(Fig. 2) [160]. Of all these aggregation intermediates, it is
currently thought that the early ones are cytotoxic and that
aggregation may be a neuroprotective response to perma-
nently sequester these intermediates, thereby preventing
potentially toxic interactions with other proteins in the
cellular milieu [162–165]. In support of this hypothesis, it
has been shown that proteins rich in beta-sheet structures
aggregate with newly synthesized proteins that have not yet
become folded or with intrinsically unfolded proteins,
thereby reducing the availability of these proteins to per-
form their normal function [135]. Further evidence
demonstrating that oligomeric or protofibrillar forms of
aggregation-prone disease proteins contribute to cell toxi-
city and death is reviewed elsewhere [144, 146, 166–168].
In a nutshell, the amyloid pathway has only just started
to be described and it is not fully understood how protein
aggregation correlates with disease. At the clinicopatho-
logical level, it is striking that there are individuals with
high AD pathology (i.e., abundant amyloid deposits and
neurofibrillary tangles) that yet do not display any cogni-
tive impairment (reviewed in [169]). This fact makes it
difficult to discern what are the boundaries between normal
aging and disease. At the cellular and molecular level, what
structural properties do aggregation-prone proteins acquire
that make them toxic? This question is further complicated
by the fact that aggregation-prone proteins such as amy-
loid-beta, huntingtin or alpha-synuclein do not share
sequence, structure or function. A second question is that
of how long neuronal cells can deal with these aggregation-
prone proteins. And is their slow accumulation in the brain
a reflection of an impaired protein quality control system?
Finally, the majority of our knowledge about aggregation
intermediates has come from in vitro studies. It remains to
be shown whether oligomeric and fibrillar species exist
in vivo and what their relevance to pathogenesis is.
Genetic modifiers of proteotoxicity
Genetic screens in small model organisms
for protein aggregation in disease
The current understanding of how protein misfolding and
aggregation contributes to neurodegeneration is far from
complete. Molecular and cellular mechanisms that may
regulate neurodegenerative disorders have been discovered
in small organisms, the major ones being yeast (Saccha-
romyces cerevisiae), fly (Drosophila melanogaster) and
nematode (C. elegans) (Table 1). In general, these small
organisms are easy to grow and manipulate; their genomes
are fully sequenced and accessible in public databases; and
they provide information relatively quickly due to their
short life cycle. Moreover, the availability of resources
such as genome-wide mutant libraries (deletion, overex-
pression or RNAi-based) further adds to the attraction of
using these organisms as powerful genetic tools. Indeed,
the well-established models of several neurodegenerative
diseases, including AD, PD and polyglutamine diseases,
have now been generated in each of these small organisms
[170]. Of note is that expression of an exogenous aggre-
gation-prone protein typically exclusive to mammals can
faithfully mimic some neuropathological features, namely
the protein aggregation and toxicity phenotype seen in the
diseased brain [170, 171]. And it is this that makes models
in small organisms so attractive in the search for
Soluble 
monomer
Oligomer Protofibril nsoluble amyloid 
aggregate
Amyloid fibrils
Fig. 2 Proposed mechanism for amyloid formation. A protein loses its monomeric native state by conversion into an oligomer which can grow
further into amyloidogenic fibrils and ultimately into insoluble amyloid aggregates

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Regulation of protein homeostasis in neurodegenerative diseases: the role of coding and non-coding_ 4033
123
evolutionary conserved modifiers of proteotoxicity. These
modifiers will provide insight into disease pathology and
can be further explored as targets for therapy.
Finding modifiers of proteotoxicity in such models can
be relatively quick: researchers can take advantage of high-
throughput screening techniques using genome-wide
overexpression, deletion, or RNAi libraries or using
chemical mutagenesis. These resources are unbiased
methods that can be used to screen for genes that—when
mutated, overexpressed or suppressed—contribute to an
increase or decrease of protein aggregation and toxicity.
Some of the hits that result from these screens may very
well be genes that have already been associated with dis-
ease in humans. On the other hand, it is also a way of
identifying previously unknown regulators of proteotoxic-
ity—such findings may provide mechanistic insights into
that particular disease. It should be noted, however, that
genes shown to strongly suppress or enhance aggregation
in one model do not always have a similar effect in other
models, possibly due to the inherent differences between
species or between the methods employed. Nevertheless,
functionally conserved genetic modifiers of aggregation
and toxicity have been identified across species.
In the end, to establish the value of genes discovered to
be involved in aggregation and toxicity in small organisms,
the results will have to be reproduced in human neurons
and in mammalian animal models. If the function of
modifiers of proteotoxicity identified in small organisms is
evolutionarily conserved, their mammalian counterparts
may become therapeutic targets worthy of future pharma-
cological investigation (Table 1). At the same time, small
model organisms provide a simple platform that can be
used not only to understand the basic mechanisms under-
lying the causal gene of disease but also as a
pharmacological screening tool. Below we describe
examples of genetic modifiers that have been studied in
different model organisms for PD, AD and polyglutamine
diseases.
Parkinson’s disease models
Alpha-synuclein is the major constituent of the protein
aggregates found in the brains of PD patients, which are
also known as Lewy bodies [172]. It is a 140-amino acid
protein that is mostly expressed in the brain and is thought
to have a function at the synapse (reviewed in [126, 173]).
The aggregation phenotype is successfully recapitulated
in the budding yeast S. cerevisiae, where heterologous
expression of alpha-synuclein induces toxicity in a con-
centration-dependent manner and is associated with the
formation of cytoplasmic protein aggregates similarly to
those observed in the human brain [174]. The character-
istics that make yeast a powerful genetic tool for studying
neurodegenerative disorders are reviewed elsewhere [171,
175].
In yeast, Cooper et al. demonstrated that overexpression
and subsequent accumulation of alpha-synuclein impairs
vesicle transport from the ER to the Golgi (Table 1) [176].
In the same study, a genome-wide overexpression screen
identified the small GTPase Ypt1 as a modifier of alpha-
synuclein toxicity. Overexpression of Ypt1p was sufficient
to prevent alpha-synuclein toxicity, by enabling forward
trafficking from the ER to the Golgi. This observation was
further extended to Drosophila and C. elegans models of
PD as well as in rat midbrain primary neurons, where
Rab1—the functionally conserved ortholog of Ypt1p—
suppressed dopaminergic neuron loss (Table 1) [176].
Another modifier of proteotoxicity identified from the
same original yeast screen was YPK9, an ortholog of the
human lysosomal P-type ATPase ATP13A2 (also known as
PARK9), an enzyme known to be associated with early
onset parkinsonism (Table 1). YPK9 overexpression pre-
vented alpha-synuclein-induced toxicity by reducing
intracellular aggregation and restoring alpha-synuclein
localization to the plasma membrane [177]. The same
study showed that the C. elegans ortholog CATP-6 par-
tially prevented dopaminergic neuron loss, and that
knockdown of CATP-6 increased alpha-synuclein mis-
folding in an age-dependent manner. Finally, in rat primary
neuron cultures transduced with a lentivirus carrying the
familial alpha-synuclein A53T mutation, heterologous
expression of human ATP13A2 prevented neuronal loss
(specifically dopaminergic neurons). Notably, this study
was the first to show a link between environmental and
genetic causes of PD, since YPK9 protected against man-
ganese toxicity in yeast, a heavy metal thought to be risk
factor for PD. Indeed, YPK9 was later shown to regulate
manganese tolerance via diverse cellular processes, such as
vesicle transport, vacuolar organization and chromatin
remodeling in yeast (Table 1) [178].
The important role of vesicle-mediated transport in
alpha-synuclein toxicity has also been demonstrated by
other studies [179, 180]. In a screen performed by Kuwa-
hara et al., the authors discovered ten neuroprotective
genes, four of which were involved in endocytosis.
Knockdown of two of these genes (apa-2 and aps-2,
encoding two different subunits of the AP-2 adaptor protein
which mediates clathrin-dependent endocytosis) revealed
that deficiencies at synaptic vesicles led to alpha-synuclein
neurotoxicity [179].
Several modifiers of proteotoxicity have also been
identified using RNAi screens in C. elegans models of PD
[179–181]. Follow-up on this work has revealed tdo-2 as a
general regulator of proteotoxicity and lifespan [182].
Genetic screens not only help us to identify novel
modifiers of proteotoxicity, but they can also be useful for
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rediscovering genes that were previously known to be
associated with disease. Such an example comes from work
by Hamamichi et al., where an RNAi screen identified the
autophagy-related gene Atgr7 as protecting against alpha-
synuclein-induced toxicity in C. elegans dopaminergic
neurons [181]. The mammalian ortholog of Atgr7 has
previously been implicated in neurodegeneration in mice,
where it was found to cause axonal degeneration and
dystrophy when ablated, thereby highlighting the impor-
tance of neuronal autophagy in preventing degeneration
(Table 1) [183].
Alzheimer’s disease models
The brains of patients with AD are characterized by the
presence of amyloid plaques and neurofibrillary tangles,
which develop as a result of an accumulation of extracel-
lular deposition of two different proteins: amyloid-beta in
the plaques and intracellular hyperphosphorylated tau in
the tangles (reviewed in [184, 185]). The disease can be
caused by a mutation in the gene for amyloid precursor
protein (APP), or in presenilin 1 or presenilin 2, all of
which alter amyloid production (reviewed in [184, 186]).
C. elegans has been a fundamental tool for dissecting
the pathways that link lifespan to AD (Table 1). Specifi-
cally, one of the major pathways that regulates lifespan is
the insulin/IGF-1 signaling (IIS) pathway—a pathway that
has been validated in nematodes, flies and mice and
strongly implicated in humans [187–193]. In one of the
models that recapitulates AD, C. elegans expresses a
human amyloid-beta protein fragment (peptide 3–42) in the
body wall muscle and progressive paralysis is used as
readout for amyloid-beta toxicity [194]. In this model,
knockdown of the insulin/IGF-1 receptor DAF-2 not only
significantly extended lifespan but also prevented amyloid-
beta toxicity by delaying the onset of paralysis, identifying
a link between the mechanisms of aging and proteotoxicity
[195]. Modulation of lifespan by DAF-2 was also found to
be highly dependent on HSF-1 and DAF-16, two tran-
scription factors known to drive the expression of longevity
genes [196]. Curiously, while both blocked proteotoxicity,
they did so through opposing effects: while HFS-1 pro-
moted disaggregation, DAF-16 pushed aggregation
forward, possibly as a means of sequestering the amy-
loidogenic protein from the cellular milieu [195].
The observation that inhibition of the IIS pathway pro-
tects against proteotoxicity was further confirmed in an AD
mouse model with haploinsufficiency of IGFR-1, the
mammalian ortholog of DAF-2 (Table 1) [197]. Here,
reducing only half the expression of IGFR-1 (and thereby
the IIS pathway) was sufficient to prevent amyloid-beta
toxicity, namely by reducing inflammation and neuron loss.
The AD mice with reduced IGFR-1 also performed better
in memory and learning tasks than their age-matched AD
controls did and this was found to be correlated with the
formation of densely packed aggregates in the brain. This
supports the idea that aggregation is a protective mecha-
nism to permanently sequester smaller, soluble oligomeric
amyloid-beta species that are proteotoxic.
The importance of modeling neurodegenerative diseases
in small organisms has been further reinforced by Treusch
et al., who have identified modifiers of amyloid-beta toxi-
city that are conserved from yeast to humans (Table 1)
[198]. Taking advantage of a yeast model of AD, they
performed an unbiased genetic screen for modifiers of
amyloid-beta toxicity. Of the identified modifiers, six were
found to be risk factors for AD in humans—either vali-
dated or potential—that had been previously identified
from family-based genome-wide association studies
(GWAS). These modifiers were specific to amyloid-beta, in
that in yeast they did not prevent toxicity induced by
another aggregation-prone protein, alpha-synuclein.
Another modifier of amyloid-beta toxicity identified by
Treusch et al. is YAP1802, a suppressor of amyloid-beta
proteotoxicity that is involved in clathrin-mediated endo-
cytosis. Its human homolog PICALM is also involved in
endocytosis and has been validated as a high-risk factor for
AD (Table 1). YAP1802 prevents amyloid-beta toxicity in
yeast and the human homolog PICALM prevents amyloid-
beta toxicity in rat cortical neurons. Notably, this study
identifies a causal gene for susceptibility to AD and pro-
poses defective endocytosis as a contributing factor in AD
pathology, with a possible role for PICALM.
In another independent study, GWAS data for AD were
combined with a functional screen in Drosophila (Table 1)
[199]. From a set of GWAS variants obtained from patients
with AD, Shulman et al. found 19 evolutionarily conserved
orthologs in the fly that either enhanced or suppressed
neurotoxicity associated with tau. Six of these interacted
with tau in vivo, including the glucose transporter GLUT1,
found to be functionally conserved in the human ortholog
SLC2A14, further supporting a role for this risk factor as a
disease modifying factor (Table 1) [199].
Polyglutamine disease models
In addition to models for PD and AD, there are several
other models for aggregation-prone proteins, which include
those for human polyglutamine diseases such as Hunting-
ton’s disease. In polyglutamine diseases, trinucleotide
repeats cause expanded tracts of the amino acid glutamine
in the encoded protein. In one C. elegans model, the ani-
mals express expanded glutamine repeats fused to a
fluorescent protein in the body wall muscle. Expression of
35–40 glutamines is sufficient to cause aggregation, which
increases with aging and is correlated with toxicity [200].
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This model has been used in at least two genome-wide
RNAi screens performed to search for suppressors and
enhancers of proteotoxicity [201, 202]. These screens
identified genes involved in RNA metabolism, as well as in
protein synthesis, folding, trafficking and degradation as
polyglutamine modifiers. In a subsequent screen to look for
more modifiers, it was found that polyglutamine aggrega-
tion is not always coupled with proteotoxicity [201].
In an EMS screen to find genes that drive aggregation,
van Ham et al. identified MOAG-4 (modifier of aggrega-
tion) as an aggregation-promoting factor in disease models
expressing polyglutamine, alpha-synuclein and amyloid-
beta, establishing MOAG-4 as a general regulator of pro-
teotoxicity (Table 1) [203]. MOAG-4 is thought to be
active during the early steps of the aggregation process,
where it drives the formation of compact aggregation
intermediates [203]. MOAG-4 is functionally conserved in
two human orthologs, SERF1A and SERF2, which have
the same aggregation-promoting function in human cell-
based models of polyglutamine diseases (Table 1) [203].
Recent insights into the function of one of these proteins,
SERF1A, suggest that it acts as an amyloid-promoting
factor [204]. In this study, SERF1A recognized a broad
range of aggregation-prone proteins (alpha-synuclein,
huntingtin, amyloid-beta, prion protein) and mediated their
conversion into amyloid in vitro [204]. It was further
demonstrated that, to do this, SERF1A interacted directly
with the monomeric form of the protein to seed amyloid
growth, therefore supporting the hypothesis that MOAG-4/
SERF1A acts on the early intermediates of the amyloid
pathway [204]. SERF1A did not promote aggregation of
non-amyloidogenic proteins.
An RNAi screen performed by Lejeune et al. identified
662 modifiers that regulate polyglutamine-induced pro-
teotoxicity in C. elegans touch receptor neurons, 49 of
which were found to be differentially expressed in two
mouse models of HD (Table 1) [205].
Another protein originally identified as a suppressor of
polyglutamine aggregation in a C. elegans model is the
chaperonin CCT [202]. It is composed of eight subunits
and, together with HSP70, is involved in de novo folding of
newly synthesized proteins [12]. Its ortholog, TRiC (also
known as TCP), was shown to cooperate with HSP70 to
prevent proteotoxicity by promoting the formation of non-
toxic, soluble polyglutamine oligomers in a yeast model
[206]. TRiC also modulated proteotoxicity in mouse and
human cell models (Table 1) [207]. The subunit CCT1 was
also shown to physically interact with polyglutamine to
suppress aggregation in vitro, supporting the hypothesis
that TRiC binds to polyglutamine to prevent it from
acquiring a potentially toxic conformation [207].
Finally, a modifier identified in yeast is the kynurenine
3-monooxygenase BNA4, whose deletion prevented
proteotoxicity induced by mutant huntingtin [208]. Follow-
up work showed that genetic ablation or pharmacological
inhibition of the ortholog KMO prevented toxicity in a fly
and mouse model for HD (Table 1) [209, 210].
In summary, small model organisms including yeast,
flies and nematodes are powerful tools for identifying
genes involved in protein aggregation and toxicity. Several
examples where small animal organisms complement
findings from human cell models or mouse models further
validate the importance of using these small animal
models.
Non-coding RNA in neurodegeneration
When the Human Genome Project started in 1990, it was
estimated that 30,000–40,000 protein coding genes would
be found in the human genome [211]. When the project
was completed in 2001, researchers were surprised to find
far fewer protein coding genes than expected, namely
21,000, representing only about 2 % of the total genome—
with the remaining 98 % being considered as ‘‘junk DNA’’
[212, 213]. However, it soon became clear that this ‘‘junk
DNA’’ actually contained regulatory elements such as non-
coding RNA (ncRNA), transcription factor binding sites or
certain chromatin structures that govern gene expression.
These conserved functional elements in the human genome
were subsequently comprehensively identified and char-
acterized [214]. Within these conserved functional
elements, many classes of ncRNA were identified and the
list has been growing ever since ([215, 216], also reviewed
in [217]). Indeed, the number of ncRNA transcripts is far
greater than those coding for proteins and the list of all
existing ncRNAs is not yet complete [218]. What we do
know is that there are different classes of ncRNA with
essential functions in gene transcription, RNA processing
and translation, a selection of which is presented in Table 2
(a more complete list can be found in [217]). Indeed,
impaired RNA metabolism has been correlated with sev-
eral neurodegenerative diseases. For example, abnormal
repeat expansions in the non-coding regions of disease-
related genes induce toxic gain-of-function of RNA in
myotonic dystrophy, amyotrophic lateral sclerosis, and
frontotemporal dementia [219, 220]. For the purpose of this
review, we focus on a few examples of ncRNAs that have
been directly implicated in neurological or neurodegener-
ative diseases (Table 2).
microRNAs
Over the past few years, it has become evident that
ncRNAs are key players in the development and mainte-
nance of the nervous system. Of all classes of ncRNAs
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identified so far, microRNAs (miRNAs) are those that have
been most extensively studied and documented. The
function of miRNAs is to bind to the 30-untranslated region
(30 UTR) of messenger RNA and inhibit its translation or
target it for degradation (Table 2) [221]. In situ
hybridization studies in mouse and zebrafish have revealed
miRNA to be expressed throughout the brain; these studies
have also demonstrated that miRNA expression is spa-
tiotemporally controlled, supporting a biological function
for miRNAs in the central nervous system [222–224].
Indeed, several hundreds of miRNAs are involved in brain
development [225–229]. miRNAs play a role in virtually
every aspect of brain function including neurogenesis,
neural differentiation and maintenance, and synaptic
plasticity, all of which are described extensively elsewhere
[230–232].
miRNAs have also been associated with various aspects
of aging and neurodegenerative diseases (Table 2) [233–
237]. For example, Northern blotting experiments in the
hippocampi of fetuses, adults and AD patients have shown
that miRNA expression changes during development and
during aging [237]. In these experiments, miR-9 and miR-
128 were upregulated in the AD hippocampus relative to
age-matched controls, hinting that these miRNAs may be
regulating the expression of genes required for pathogen-
esis. At least two other human studies have shown an
association between miRNAs and the beta-site APP
cleaving enzyme 1 (BACE-1), which is responsible for
cleaving APP into the amyloid-beta 1-42 toxic species
[235, 236]. In these studies, the expression of miR-107,
miR-29a and miR-29b-1 was decreased in the AD brain
while expression of BACE-1 was increased (Fig. 4a) [235,
236]. Since these miRNAs target the 30 UTR of BACE-1, it
follows that miRNAs can reduce BACE-1 mRNA levels
and, therefore, amyloid-beta 1-42 generation in the brain,
an effect that is lost in the diseased brain due to the
reduced expression of these miRNAs (Fig. 4a) [235, 236].
In a mouse model for AD, miR-34a is thought to inhibit
bcl-2, an anti-apoptotic gene that prevents cell death pro-
voked by amyloidogenic species (Fig. 4b) [234].
Additionally, miR-124 has been found to regulate APP
alternative splicing in neurons [233].
In PD, downregulation of the miR-34b/c cluster is cor-
related with downregulation of DJ-1 and Parkin, two genes
implicated in the pathogenesis of PD, although a causal
link has yet to be determined [238]. It has recently been
shown in a cell model that this same cluster directly
represses alpha-synuclein mRNA levels and consequently
aggregate formation, establishing that miRNAs can have a
direct effect on the expression of an aggregation-prone
protein [239].
Several miRNAs have also been found to be dysregu-
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HD, REST is a transcription factor that negatively regulates
neuronal gene expression and has been found to repress
brain-specific miRNAs in mouse and human brains [241,
242]. Two of these miRNAs, miR-9 and miR-9*, have been
identified as targeting the REST complex in a negative
feedback loop [244]. In a cell model of spinocerebellar
ataxia type 1, miR-19, miR-101 and miR-130 coopera-
tively regulate ataxin-1 expression levels by binding to its
30 UTR [243]. Inhibition of these miRNAs leads to ataxin-1
accumulation in cells and subsequent cell death [243].
tRNAs
Transfer RNAs are essential for mRNA translation into a
protein, as they are responsible for transporting the cognate
amino acid to the nascent polypeptide chain (Table 2)
[245, 246]. Due to the degeneracy of the genetic code,
there can be up to five tRNAs per amino acid—termed
isoacceptors—that have distinct anticodons for recognizing
the same amino acid [245, 246]. On the other hand, tRNAs
that share the same anticodon but have distinct body
sequences are termed isodecoders, and their number vary
greatly [246].
Growing evidence suggests that mutations in individual
tRNAs—or in the enzymes involved in their biosynthesis—
are a contributing factor in neurodegeneration (Fig. 3)
[247–252]. For example, a point mutation (4274T[C) in
the mitochondrial tRNA for isoleucine was identified in a
patient suffering from motor neuron disease, although the
mechanism by which this mutation might lead to disease is
unknown (Fig. 3a) [252]. In a recent study, loss of function
of one of the brain-specific tRNA isodecoders for arginine
was found to be correlated with neurodegeneration in mice
(Fig. 3a) [247]. Specifically, a point mutation (50C[T) in
the T loop of the arginine tRNA provoked ribosome stal-
ling, which is normally offset by GTPBP2. However,
simultaneous impairment of GTPBP2 in these mice dis-
abled its function as a so-called rescue factor, subsequently
resulting in neurodegeneration [247].
Other impairments in the tRNAs biosynthesis pathway
are seen in pontocerebellar hypoplasia (PHC). PHC is an
autosomal recessive neurodegenerative disorder that has
six subtypes (PHC1-6) and is generally characterized by
hypoplasia and atrophy of the cerebellum and pons [253].
PHC2 and PHC4 arise from impaired tRNA splicing
endonuclease (TSEN) activity. TSEN is composed of two
catalytic subunits (TSEN 2 and TSEN34) and two non-
catalytic subunits (TSEN54 and TSEN15) (Fig. 3c) [250,
254]. It is thought that mutations in both catalytic subunits
and in TSEN54 may prevent proper complex formation,
leading to misplicing of premature tRNAs (pre-tRNAs)
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Fig. 3 Mutations in the tRNA biosynthesis pathway that lead to
neurodegeneration. The point mutation (50C[T) in the T loop of one
tRNA isoacceptor for arginine (Arg) provokes neurodegeneration.
Another described point mutation (4274T[C) in the mitochondrial
tRNA for isoleucine (Ile) has also been associated with motor neuron
disease (a). Following transcription, the 50 leader sequence of the pre-
tRNA is removed by RNAseP, the 30 end is processed by RNAse Z
and the trinucleotide CCA is added to the 30 end by a nucleotidyl
transferase (b). Different bases of the RNA transcript can undergo
chemical modifications (c). The introns of the pre-tRNA are spliced
out by a tRNA splicing endonuclease (TSEN). Mutations in these
enzymes have been associated with pontocerebellar hypoplasia (PHC)
and mutations in their co-factor CLP-1 with motor neuron loss (d).
Finally, the mature tRNA is loaded with an amino acid (aa) via tRNA
synthetases (e)
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repertoire for protein synthesis [248, 250]. PHC6 results
from a mutation in the intronic region of the mitochondrial
pre-tRNA synthetase gene for arginine [251].
Finally, CLP-1 is a mammalian kinase that cooperates
with the TSEN complex to remove the intronic loop of pre-
tRNAs (Fig. 3c) [255]. Loss of CLP-1 results in severe
impairment of spinal motor neurons in mice, ultimately
leading to respiratory failure [255]. CLP-1 mutations in
affected patients have been correlated with neurodevelop-
ment and neurological symptoms in both the central and
peripheral nervous system [256, 257].
In summary, these studies demonstrate a crucial role for
tRNAs in neuronal function, as either mutations in their
transcript or defective post-transcriptional modifications
























Fig. 4 Impaired BACE-1 regulation contributes to AD. miR-107,
miR-29a and miR29-b-1 were shown to be decreased in the brain of
AD patients while BACE-1 mRNA and protein levels were elevated
(a). In an AD mouse model, elevated levels of miR-34a negatively
correlate with BCL-2 protein levels, which normally prevent
apoptosis induced by amyloid-beta (b). BACE-1 anti-sense transcripts
were reported to be upregulated in the brains of AD patients. BACE-1
anti-sense transcripts stabilizes BACE-1 mRNA, thereby facilitating
its expression, which ultimately results in the generation of more
amyloid-beta (c)
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Other ncRNAs
The other non-coding RNAs shown in Table 2 have been
less well studied but are nevertheless worthy of mention.
Long non-coding RNAs (lncRNAs) are more than 200
nucleotides long and are mostly expressed in the nervous
system (Table 2) ([223], also reviewed in [258]). Three
lncRNAs have been suggested to be involved in neurode-
generative diseases. Firstly, BACE-1 anti-sense transcript
is an lncRNA that competes with miR-485-5p for binding
to the BACE-1 mRNA to stabilize it (Fig. 4c) [259]. In
AD, the levels of BACE-1 anti-sense transcript are ele-
vated, thereby stabilizing BACE-1 mRNA and enhancing
its expression, which further promotes the generation of
toxic amyloid-beta 1–42 (Fig. 4c) [259]. Secondly, in
spinocerebellar ataxia type 7 (SCA7), lncSCA-7 crosstalks
with miR-124 to regulate transcript levels of atxn7 [260].
Thirdly, Abhd11os is an lncRNA that has been shown to be
neuroprotective against mutant huntingtin in two mouse
models for HD, although the exact mechanism of how this
occurs remains to be determined [261].
Small nuclear RNAs (snRNAs) exist as small nuclear
ribonucleoproteins (snRNPs) and are major components of
the pre-mRNA splicing machinery (Table 2) [262, 263].
The survival motor neuron protein (SMN) is directly
involved in the generation of snRNPs [264]. In a mouse
model of spinal muscular atrophy, SMN deficiency affects
the snRNA pool in a tissue-specific manner, ultimately
leading to pre-mRNA splicing defects in a diverse range of
genes [264]. Further evidence for the involvement of
snRNAs in neurodegeneration comes from work by Jia
et al., who revealed that a mutation in a U2 snRNA gene
impairs alternative splicing of pre-mRNA which is directly
responsible for neuron loss in the cerebellum and hip-
pocampus of mice [265].
Neurodegeneration is clearly not exclusively caused by
imbalances in protein coding genes—it can also arise from
dysregulation of ncRNAs. Over the past two decades, we
have begun to understand that ncRNAs are not just
‘‘transcriptional noise’’ and have started to define their role
in the CNS and in neurodegeneration. Several reports have
shown that different classes of ncRNAs influence the
expression levels of the disease protein and that each class
of ncRNA does so either by affecting the protein post-
transcriptionally or through crosstalk with other classes of
ncRNAs (miRNAs, lncRNAs). Maintaining a proper
environment for protein synthesis is crucial to ensure that
each mRNA molecule is effectively spliced and translated
into a protein (through tRNAs and snRNAs). To establish
the causal relationships between changes in ncRNAs and
disease phenotypes, the targets of these ncRNAs need to be
uncovered. Understanding the role of ncRNAs will provide
insight into the mechanisms of neurodegenerative diseases,
which enables the identification of targets for therapeutic
interventions.
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